Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Pharma Pushes Back Against ‘Discriminatory’ New EU Drug Pollution Proposals

European Commission Insists Its Measures Against Pharmaceutical Pollution Have Wide Support

Executive Summary

Medicines for Europe, along with EFPIA and the AESGP, say that the ‘polluter pays’ principle behind proposed new European rules on wastewater treatment would saddle pharmaceutical manufacturers with costs that “jeopardize patient access.”

You may also be interested in...



EU Raises Pressure On Pharmaceutical Pollution Of The Environment

Two EU bodies want to move forward with European Commission proposals on contamination of the environment by pharmaceutical substances.

Gloomy First Half Results For Mayne

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

Chemiphar Profit Slumps 82.5% In Q3

Plummeting sales and profit following government price regulations pushes Chemiphar to target international expansion

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel